CSCI Key Statistics, Chart & Performance
The current stock price of CSCI is 2.72 USD. In the past month the price decreased by -31.14%. In the past year, price decreased by -32%.
CSCI Technical Analysis
CSCI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CSCI. CSCI may be in some trouble as it scores bad on both profitability and health.
CSCI Financial Highlights
Over the last trailing twelve months CSCI reported a non-GAAP Earnings per Share(EPS) of -5.8. The EPS increased by 13.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -56.4% | ||
| ROE | -173.14% | ||
| Debt/Equity | 0.19 |
CSCI Forecast & Estimates
CSCI Ownership
About CSCI
Company Profile
COSCIENS Biopharma Inc. engages in the development and commercialization of diverse pharmaceutical and diagnostic products. The company is headquartered in Toronto, Ontario. The firm is developing and commercializing a diversified portfolio of products for the cosmeceutical, nutraceutical and pharmaceutical markets. The Company’s patented technologies include the Pressurized Gas eXpanded (PGX) technology, which is a technology that generates high-value yields of active ingredients from natural-based resources for use in novel cosmeceutical, nutraceutical and pharmaceutical products. The firm's two products, oat beta glucan and avenanthramides, are found in household-name cosmetic and personal care brands. These products are manufactured from the Company’s proprietary oat extraction manufacturing technology and are known for their well-documented health benefits. Its lead product, macimorelin (Macrilen; Ghryvelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD).
Company Info
COSCIENS BIOPHARMA INC
C/O Norton Rose Fulbright Canada Llp, 222 Bay Street, Suite 3000, Po Box 53
TORONTO ONTARIO CA
Employees: 21
Phone: 18439003201
COSCIENS BIOPHARMA INC / CSCI FAQ
What does CSCI do?
COSCIENS Biopharma Inc. engages in the development and commercialization of diverse pharmaceutical and diagnostic products. The company is headquartered in Toronto, Ontario. The firm is developing and commercializing a diversified portfolio of products for the cosmeceutical, nutraceutical and pharmaceutical markets. The Company’s patented technologies include the Pressurized Gas eXpanded (PGX) technology, which is a technology that generates high-value yields of active ingredients from natural-based resources for use in novel cosmeceutical, nutraceutical and pharmaceutical products. The firm's two products, oat beta glucan and avenanthramides, are found in household-name cosmetic and personal care brands. These products are manufactured from the Company’s proprietary oat extraction manufacturing technology and are known for their well-documented health benefits. Its lead product, macimorelin (Macrilen; Ghryvelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD).
What is the current price of CSCI stock?
The current stock price of CSCI is 2.72 USD. The price decreased by -11.69% in the last trading session.
Does COSCIENS BIOPHARMA INC pay dividends?
CSCI does not pay a dividend.
How is the ChartMill rating for COSCIENS BIOPHARMA INC?
CSCI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the GICS sector and industry of CSCI stock?
COSCIENS BIOPHARMA INC (CSCI) operates in the Health Care sector and the Biotechnology industry.
Can you provide the PE ratio for CSCI stock?
COSCIENS BIOPHARMA INC (CSCI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.8).